537 related articles for article (PubMed ID: 17965103)
21. Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: a randomized clinical trial.
Bonini-Filho MA; Jorge R; Barbosa JC; Calucci D; Cardillo JA; Costa RA
Invest Ophthalmol Vis Sci; 2005 Oct; 46(10):3845-9. PubMed ID: 16186372
[TBL] [Abstract][Full Text] [Related]
22. Posterior sub-Tenon's capsule injection of triamcinolone acetonide prevents panretinal photocoagulation-induced visual dysfunction in patients with severe diabetic retinopathy and good vision.
Shimura M; Yasuda K; Shiono T
Ophthalmology; 2006 Mar; 113(3):381-7. PubMed ID: 16458970
[TBL] [Abstract][Full Text] [Related]
23. Posterior subtenon triamcinolone, intravitreal triamcinolone and grid laser photocoagulation for the treatment of macular edema in branch retinal vein occlusion.
Ozdek S; Deren YT; Gurelik G; Hasanreisoglu B
Ophthalmic Res; 2008; 40(1):26-31. PubMed ID: 18025838
[TBL] [Abstract][Full Text] [Related]
24. One-year safety and efficacy of intravitreal triamcinolone acetonide for the management of macular edema secondary to central retinal vein occlusion.
Gregori NZ; Rosenfeld PJ; Puliafito CA; Flynn HW; Lee JE; Mavrofrides EC; Smiddy WE; Murray TG; Berrocal AM; Scott IU; Gregori G
Retina; 2006 Oct; 26(8):889-95. PubMed ID: 17031288
[TBL] [Abstract][Full Text] [Related]
25. Outcome of intravitreal triamcinolone acetonide in postoperative cystoid macular oedema.
Konstantopoulos A; Williams CP; Luff AJ
Eye (Lond); 2008 Feb; 22(2):219-22. PubMed ID: 17016463
[TBL] [Abstract][Full Text] [Related]
26. Intravitreal triamcinolone acetonide in patients with macular oedema due to central retinal vein occlusion.
Krepler K; Ergun E; Sacu S; Richter-Müksch S; Wagner J; Stur M; Wedrich A
Acta Ophthalmol Scand; 2005 Feb; 83(1):71-5. PubMed ID: 15715561
[TBL] [Abstract][Full Text] [Related]
27. Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema secondary to branch retinal vein occlusion.
Cheng KC; Wu WC; Chen KJ
Eye (Lond); 2009 Nov; 23(11):2023-33. PubMed ID: 19798117
[TBL] [Abstract][Full Text] [Related]
28. Outcome of intravitreal triamcinolone in uveitis.
Kok H; Lau C; Maycock N; McCluskey P; Lightman S
Ophthalmology; 2005 Nov; 112(11):1916.e1-7. PubMed ID: 16171868
[TBL] [Abstract][Full Text] [Related]
29. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial.
Gillies MC; Sutter FK; Simpson JM; Larsson J; Ali H; Zhu M
Ophthalmology; 2006 Sep; 113(9):1533-8. PubMed ID: 16828501
[TBL] [Abstract][Full Text] [Related]
30. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion.
Ip MS; Gottlieb JL; Kahana A; Scott IU; Altaweel MM; Blodi BA; Gangnon RE; Puliafito CA
Arch Ophthalmol; 2004 Aug; 122(8):1131-6. PubMed ID: 15302652
[TBL] [Abstract][Full Text] [Related]
31. Microperimetric changes after intravitreal triamcinolone acetonide injection for macular edema due to central retinal vein occlusion.
Senturk F; Ozdemir H; Karacorlu M; Karacorlu SA; Uysal O
Retina; 2010 Sep; 30(8):1254-61. PubMed ID: 20827142
[TBL] [Abstract][Full Text] [Related]
32. Fluocinolone acetonide sustained drug delivery device for chronic central retinal vein occlusion: 12-month results.
Ramchandran RS; Fekrat S; Stinnett SS; Jaffe GJ
Am J Ophthalmol; 2008 Aug; 146(2):285-291. PubMed ID: 18533125
[TBL] [Abstract][Full Text] [Related]
33. Posterior subtenon and intravitreal triamcinolone acetonide for diabetic macular edema.
Ozdek S; Bahçeci UA; Gürelik G; Hasanreisoğlu B
J Diabetes Complications; 2006; 20(4):246-51. PubMed ID: 16798476
[TBL] [Abstract][Full Text] [Related]
34. 25-gauge vitrectomy and triamcinolone acetonide-assisted internal limiting membrane peeling for chronic cystoid macular edema associated with branch retinal vein occlusion.
Ma J; Yao K; Zhang Z; Tang X
Retina; 2008; 28(7):947-56. PubMed ID: 18698296
[TBL] [Abstract][Full Text] [Related]
35. Posterior juxtascleral infusion of modified triamcinolone acetonide formulation for refractory diabetic macular edema: one-year follow-up.
Veritti D; Lanzetta P; Perissin L; Bandello F
Invest Ophthalmol Vis Sci; 2009 May; 50(5):2391-7. PubMed ID: 19117937
[TBL] [Abstract][Full Text] [Related]
36. Intravitreal triamcinolone for macular oedema: efficacy in relation to aetiology.
Sørensen TL; Haamann P; Villumsen J; Larsen M
Acta Ophthalmol Scand; 2005 Feb; 83(1):67-70. PubMed ID: 15715560
[TBL] [Abstract][Full Text] [Related]
37. Objective evaluation of cataract progression associated with a high dose intravitreal triamcinolone injection.
Chu YK; Chung EJ; Kwon OW; Lee JH; Koh HJ
Eye (Lond); 2008 Jul; 22(7):895-9. PubMed ID: 17435692
[TBL] [Abstract][Full Text] [Related]
38. Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases.
Jonas JB
Acta Ophthalmol Scand; 2005 Dec; 83(6):645-63. PubMed ID: 16396641
[TBL] [Abstract][Full Text] [Related]
39. Intravitreal triamcinolone acetonide for patients with macular edema due to branch retinal vein occlusion.
Cheng KC; Wu WC
Kaohsiung J Med Sci; 2006 Jul; 22(7):321-30. PubMed ID: 16849100
[TBL] [Abstract][Full Text] [Related]
40. Intravitreal bevacizumab versus triamcinolone acetonide for macular edema due to branch retinal vein occlusion: a matched study.
Hou J; Tao Y; Jiang YR; Li XX; Gao L
Chin Med J (Engl); 2009 Nov; 122(22):2695-9. PubMed ID: 19951598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
